


FEB 28 2013

SENATE

S. NO. 3140

(In substitution of Senate Bill Nos. 746 and 2163)

REF. 

Prepared by the Committees on Civil Service and Government Reorganization; and Finance, with Senators Ejercito-Estrada, Escudero, and Trillanes IV as authors thereof

AN ACT
REGULATING THE PRACTICE OF PHARMACY IN THE PHILIPPINES,
REPEALING FOR THE PURPOSE REPUBLIC ACT NO. 5921, THE PHARMACY
LAW, AS AMENDED, AND FOR OTHER PURPOSES

Be it enacted by the Senate and House of Representatives of the Philippines in Congress assembled:

ARTICLE I

GENERAL PROVISIONS

1
2
3 SECTION 1. *Title.* - This Act shall be known as the "*Philippine Pharmacy Act of*
4 *2012*".

5
6 SEC. 2. *Statement of Policy.* The State recognizes the vital role of pharmacists in quality
7 healthcare delivery through their services in providing safe, effective, and quality drugs or
8 medicines; drug information, patient medication counseling, and health promotion. The
9 pharmacists' professional service shall, therefore, be promoted as a component of the total
10 healthcare system, which shall ensure the physical well-being of the Filipinos.

11 Hence, the state shall develop and nurture competent, productive, morally upright, and
12 well-rounded pharmacists whose standards of professional practice and service shall be
13 excellent, qualitative, world-class and internationally recognized, globally competitive through
14 regulatory measures, programs, and activities that foster their continuing professional
15 development.

1 **SEC. 3. Objectives.** - This Act provides for, and shall govern:

- 2 (a) the standardization and regulation of pharmacy education,
3 (b) the examination for registration of graduates of schools and colleges of pharmacy,
4 (c) the supervision, control, and regulation of the practice of pharmacy in the
5 Philippines,
6 (d) the enhancement of professional competence through continuing professional
7 development, research, and other related activities, and
8 (e) the integration of the pharmacy profession.

9
10 **SEC. 4. Definition of Terms.** – For purposes of this Act, the term:

- 11 (a) “*Biopharmaceuticals*” are vaccines, sera and drugs derived from life forms using
12 biotechnology. They include proteins, nucleic acids and living microorganisms
13 like viruses and bacteria where the virulence is reduced by attenuation used for
14 therapeutic or *in vivo* diagnostic purposes.
15 (b) “*Brand Name*” means the proprietary or trade name given by the manufacturer to
16 distinguish its product from those of the competitors;
17 (c) “*Cipher*” means a method of secret writing that substitutes other letters or characters for
18 the letter intended or transpose the letter after arranging them in blocks or squares;
19 (d) “*Code*” means a system of words or other symbols arbitrarily used to represent words;
20 (e) “*Compounding*” is the preparation, mixing, assembling, packaging, or labeling of a drug
21 (i) as the result of a prescription or drug order by a physician, dentist, optometrist, or
22 veterinarian, based on the said practitioner-patient-pharmacist relationship in the course
23 of professional practice, or (ii) for the purpose of, or in relation to, research, teaching, or
24 chemical analysis;
25 (f) “*Cosmetics*” are substances or preparations intended to be placed in contact with the
26 various external parts of the human body or with the teeth and the mucous membranes of
27 the oral cavity, with a view exclusively or mainly to clean them or perfume them,
28 changing their appearance and/or correcting body odor, and/or protecting the body or
29 keeping them in good condition. (RA 9711);

1 (g) "*Counterfeit drug/medicine/pharmaceutical*" refers to medicinal products with the
2 correct ingredients but not in the amounts as provided, wrong ingredient, without active
3 ingredient/s, with insufficient quantity of active ingredient, which result in the reduction
4 of the drug's safety, efficacy, quality, strength or purity. It is a drug that is deliberately
5 and fraudulently mislabeled with respect to identity and/or source or with fake packaging,
6 and can apply to both branded and generic products. It shall also refer to:

- 7 1) the drug itself or the container or labeling thereof or any part of such drug,
8 container, or labeling bearing without authorization the trademark, trade name
9 or other identification mark or imprint or any likeness to that which is owned or
10 registered in the Intellectual Property Office (IPO) in the name of another
11 natural or juridical person;
- 12 2) a drug product refilled in containers by unauthorized persons if the legitimate
13 labels or marks are used;
- 14 3) an imported drug product not registered with the Food and Drug Administration
15 (FDA), except drugs brought in the country for personal use as confirmed and
16 justified by accompanying medical records; and
- 17 4) a drug which contains no amount of a different active ingredient or less than
18 eighty percent (80%) of the active ingredient it purports to possess as
19 distinguished from an adulterated drug including reduction or loss of efficacy
20 due to expiration.

21 (h) "*Dangerous drugs*" include those listed in the Schedules annexed to the 1961 Single
22 Convention on Narcotic Drugs as amended by the 197 Protocol, and in the Schedules
23 annexed to the 1971 Single Convention on Psychotropic Substances as enumerated in the
24 attached annex in Republic Act No. 9165, which is an integral part of the Act;

25 (i) "*Dispensing*" is a process of reading, checking, and interpretation of prescription,
26 preparing, packaging, labeling, record keeping, and sale or transfer of drugs and
27 medicines with or without a prescription or medication order which process includes
28 counseling and information giving by or under supervision of a duly registered and
29 licensed pharmacist;

- 1 (j) *"Drugs and Medicines"* refer to chemical compounds or biological substances, other
2 than food, intended for use in the treatment, prevention or diagnosis of disease in humans
3 or animals, including but not limited to:
- 4 1) any article recognized in the official United States Pharmacopoeia,-National
5 Formulary, official Homeopathic Pharmacopoeia of the United States, Philippine
6 Pharmacopoeia, Philippine National Drug Formulary, British Pharmacopoeia,
7 European Pharmacopoeia, Japanese Pharmacopoeia, and any official compendium or
8 any supplement to them;
 - 9 2) any article intended for use in diagnosis, cure, mitigation, treatment, or prevention of
10 disease of man and animals;
 - 11 3) any article other than food intended to affect the structure or any function of the
12 human body or animals;
 - 13 4) any article intended for use as a component of articles specified in clauses (1), (2),
14 and (3) not including devices or their components, parts, accessories; and
 - 15 5) herbal and/or traditional drugs which are articles of plant or animal origin used in folk
16 medicine which are: (a) recognized in the Philippine National Drug Formulary; (b)
17 intended for use in the treatment, or cure or mitigation of disease symptoms, injury or
18 body defects in humans; (c) other than food, intended to affect the structure or any
19 function of the human body; (d) in finished or ready-to-use dosage form; and (e)
20 intended for use as a component of any of the articles specified in clauses (a), (b), (c)
21 or (d);
- 22 (k) *"Drug or Pharmaceutical Laboratory or Pharmaceutical Manufacturing Laboratory"*
23 means an establishment where pharmaceutical products, proprietary medicines, or
24 pharmaceutical specialties are formulated, prepared, compounded, and standardized;
- 25 (l) *"Drug Establishments"* means FDA-registered companies involved in the manufacture,
26 importation, repacking, and/or distribution of drugs or medicines;
- 27 (m) *"Drug Outlets"* refer to drugstores, pharmacies, and other business establishments which
28 are registered with the FDA and which legally sell drugs and medicines;

- 1 (n) *“Drugstore”* or *“Pharmacy”* means a place or establishment licensed by FDA where
2 drugs, chemicals, pharmaceutical products, specialties, and devices are legally sold at
3 retail or wholesale and where medical, dental, and veterinary prescriptions are
4 compounded and dispensed;
- 5 (o) *“Emergency cases”* refer to life-threatening situations where a patient needs
6 immediate medical attention and treatment or the occurrence of an epidemic or
7 natural calamities.
- 8 (p) *“Expiration Date”* means the date until which the manufacturer can guarantee a product
9 to possess its claimed potency, efficacy, quality, and safety; and after which its sale or
10 distribution is prohibited;
- 11 (q) *“Filling”* of a prescription refers to the act of dispensing or giving out of medicines in
12 accordance with the prescriber’s medication order or prescription;
- 13 (r) *“Generic Name”* means the scientifically and internationally recognized name of the
14 active ingredient/s as approved by the Food and Drug Administration (FDA);
- 15 (s) *“Household Remedies”* shall refer to any preparation containing pharmaceutical
16 substances of common or ordinary use to relieve common physical ailments which may
17 be dispensed without a medical prescription in original packages, bottles or containers,
18 the nomenclature of which has been duly approved by FDA in the process of registration
19 as defined in FDA AO No.115 (s. 1991);
- 20 (t) *“Institutional pharmacies”* are establishments which provide, within their premises,
21 medicines to their employees and/or relatives either for free or at cost;
- 22 (u) *“Label”* means a display of written, printed or graphic information upon the immediate
23 container, or attached to or accompanying any pharmaceutical products.
- 24 (v) *“Labeling”* means all labels and other written, printed, or graphic matter (1) upon any
25 item or any of its containers or wrappers or (2) accompanying any such item;
- 26 (w) *“Medical Devices”* refer to any instrument, apparatus, implement, machine, implant, in
27 vitro reagent or calibrator, software, material or other similar or related article:
28 (a) intended by the manufacturer to be used, along or in combination, for human beings
29 for one or more of the specific purpose(s) of:

- 1 1) diagnosis, prevention, monitoring, treatment, alleviation of diseases of
- 2 diseases;
- 3 2) diagnosis, monitoring, treatment, alleviation of or compensation for an injury;
- 4 3) investigation, replacement or modification or support of the anatomy of a
- 5 physiological process;
- 6 4) supporting or sustaining life;
- 7 5) control of conception,
- 8 6) disinfection of medical devices,
- 9 7) providing information for medical or diagnostic purposes by means of an in
- 10 vitro examination of specimen derived from the human body; and,

11 (b) which does not achieve its primary intended action in or on the human body by
12 pharmacological, immunological or metabolic means, but which may be assisted in
13 their intended function by such means;

14 (x) “*Non-traditional outlets*” – other retail outlets licensed by FDA other than drugstores
15 and pharmacies where drugs are made available in conjunction with the provisions of
16 R.A. 9502.

17 (y) “*Online pharmacy*” refers to any activity of taking orders for medicines online or thru
18 the internet.

19 (z) “*Over-the-counter drugs*” are drugs used for symptomatic relief of minor ailments which
20 may be dispensed without a prescription;

21 (aa) “*Pharmaceutical products or Pharmaceutical specialties*” are drugs, preparations, or
22 mixture of drugs under a brand or generic name and intended for the cure, mitigation,
23 treatment, or prevention of disease in man or animals;

24 (bb) “*Pharmacist-only over-the-counter drugs*” are FDA-classified over-the-counter drugs
25 and/or substances which should only be obtained from a legitimate drugstore or
26 pharmacy with mandatory pharmacist’s advice on their selection and proper use;

27 (cc) “*Person*” includes an individual, partnership, corporation, or any juridical entity;

28 (dd) “*Pharmaceutical marketing*” means any activity undertaken, organized or sponsored by
29 a drug establishment which is directed at promoting the prescription, recommendation,

1 supply, administration or consumption of its pharmaceutical product(s) through direct
2 personal contact and all media, including the internet;

3 (ee) *"Pharmacy Assistants"* are persons who assist pharmacists in compounding
4 and dispensing of medicines in community, hospital, industrial settings and in
5 other activities, such as, but not limited to medical missions, under the
6 supervision of the pharmacist and as described in Section 41 of this Act.
7 Pharmacy aides/clerks are those who assist in other aspects of pharmacy
8 operation.

9 (ff) *"Physician's samples"* refer to medicines given to a physician for free for promotional
10 purposes;

11 (gg) *"Prescription drugs"* are those drugs which can only be dispensed by a pharmacist to a
12 patient upon the presentation of a valid prescription from a physician, dentist, optometrist
13 or veterinarian and for which pharmacist's advice on their proper use is necessary;

14 (hh) *"Professional Medical Representative or Company Sales Representative"* is one who
15 represents any duly authorized manufacturer, distributor, trader and wholesaler of drugs,
16 pharmaceuticals, biologic products and devices, whose primary duty is to introduce said
17 products to legitimate prescribers and which forms part of their program for promotion
18 by describing its use, composition, action, dosage, administration, contraindication,
19 advantages and other relevant information about the drugs being promoted;

20 (ii) *"Refilling"* of a prescription refers to the act of dispensing or giving out the remaining
21 balance of medicines ordered in the prescription when the whole quantity ordered is not
22 yet completely filled;

23 (jj) *"Secret Keys"* means a characteristic style or symbols kept from the knowledge of others
24 or disclosed confidentially to a few individuals;

25 (kk) *"Telepharmacy"* is the provision of pharmacy services utilizing electronic information
26 and communication technology under the supervision of a pharmacist;

27 (ll) *"Wholesaler"* means every person who acts as merchant, broker or agent, who sells or
28 distributes for resale pharmaceuticals, proprietary medicines or pharmaceutical
29 specialties.

1 **SEC. 8. *Term of Office of Board Members.*** - The chairman and the members of the
2 Board shall hold office for three (3) years after appointment or until their successors shall have
3 been appointed and duly qualified; *Provided*, the incumbent Board members shall finish their
4 terms to complete the membership of the Board. *Provided*, further, that the chairman or any
5 member may be re-appointed for another term but in no case shall he/she serve for more than six
6 years.

7
8 **SEC. 9. *Compensation of the Board of Pharmacy.*** - As provided for in R.A. No. 8981,
9 known as the “PRC Modernization Act of 2000”, the members of the Board shall receive
10 allowances and benefits equivalent to at least two salary grades lower than the salary grade of the
11 Commissioner, while the chairman of the Board shall receive a monthly compensation
12 equivalent to two steps higher than the members of the Board. The chairman and members shall
13 be entitled to other allowances and benefits provided under existing laws.

14
15 **SEC. 10. *Powers, Functions and Duties of the Board.*** – The Board shall exercise these
16 specific powers, functions, and duties:

17 (a) Conduct licensure examination for pharmacists;

18 (b) Prepare, adopt, and issue the Table of Specifications for the subjects in the board
19 licensure examination for pharmacists in consultation with the academe; determine and
20 prepare the questions therefor; score and rate the examination papers with the name and
21 signature of the Board member concerned appearing thereon and submit the results in all
22 subjects duly signed by the members of the Board to the Commission no later than three
23 (3) days from the last day of examination unless extended by the Commission for
24 justifiable cause/s;

25 (c) Review and/or amend the scope of licensure examination;

26 (d) Approve the registration of pharmacists;

27 (e) Add, delete, modify the scope, definition and standards of practice of pharmacy;

28 (f) Reprimand any pharmacist, suspend, or revoke his/her certificate of registration on the
29 grounds as provided for in Sec. 46 hereof, after a formal administrative investigation;

- 1 (g) Promulgate from time to time the necessary rules and regulations for the effective
2 enforcement of this Act;
- 3 (h) Monitor the conditions affecting the practice of pharmacy in the Philippines and adopt
4 measures that may be deemed proper for the enhancement of the profession and/or the
5 maintenance of high professional, academic, ethical and technical standards;
- 6 (i) Verify or confirm the qualifications and conditions of pharmacists employed in
7 drugstores, hospital pharmacies, drug or pharmaceutical laboratories, drug traders,
8 importers, cosmetics and medical device establishments for which the Board may
9 designate inspectors from the Food and Drug Administration and other related
10 institutions for such purpose;
- 11 (j) Investigate cases arising from violations of this Act, the rules and regulations
12 promulgated thereunder and the Pharmacist's Code of Ethics, technical standards, and
13 other Board issuances and for this purpose, may issue summons, subpoena *duces ad*
14 *testificandum* and subpoena *duces tecum* to the respondents and/or witnesses to compel
15 their attendance in such investigations or hearings: *Provided* that, the decision of the
16 Board shall, unless appealed to the Commission, become final and executory after
17 fifteen (15) days from receipt of notice of judgment or decision;
- 18 (k) Cite a person in contempt for failure or refusal to obey the lawful order of the Board in
19 accordance with the Revised Rule of Court;
- 20 (l) Delegate the hearing or investigation of administrative cases filed before them whereat
21 the hearing shall be presided over by at least one (1) member of the Board concerned
22 assisted by a Legal or Hearing Officer of the Commission, provided that if the charge is
23 not related to the technical practice of the profession, the hearing may be conducted
24 without a member of the Board;
- 25 (m) Conduct, through the Legal Officers of the Commission, summary proceedings on minor
26 violations of the respective regulatory laws, as determined by the Board. Violations of the
27 rules and regulations issued by the Board to implement this Act, including violations of
28 the general instructions to examinees committed by examinees, and render summary

1 judgment thereon which shall, unless appealed to the Commission, become final and
2 executory after fifteen (15) days from receipt of notice of judgment or decision;

3 (n) Subject to the final approval by the Commission, recommend registration without
4 examination and the issuance of corresponding certificate of registration and professional
5 identification card to foreign pharmacists duly licensed in countries with agreement of
6 reciprocity with the Philippine government;

7 (o) Prepare an annual report of accomplishments on programs, projects, and activities of the
8 Board during the year for submission to the Commission after the close of each calendar
9 year including appropriate recommendations on issues or problems affecting the practice
10 of pharmacy;

11 (p) Issue and promulgate guidelines on continuing professional development education in
12 coordination with the accredited professional organization;

13 (q) Recommend to the CHED for the closure of the program or course of pharmacy offered
14 by a school/college pursuant to the latter's policy thereon;

15 (r) Approve the certification of drug handlers covered by Sec. 41 of this Act;

16 (s) Approve the standardized training programs for pharmacy assistants, clerks, and medical
17 representatives; and,

18 (t) Perform any implied, incidental, necessary power for the effective implementation of this
19 Act.

20
21 **SEC. 11. *Grounds for Suspension or Termination of Term of Office of the Chairman***
22 ***or Member of the Board from his/her Office.*** - The President of the Philippines, upon the
23 recommendation of the Commission, after giving the Chairman or the member of the Board an
24 opportunity to defend himself/herself in an administrative investigation conducted by the
25 Commission, may remove or suspend him/her on any of the following grounds:

26 (a) Gross neglect, incompetence or dishonesty in the discharge of his/her duty;

27 (b) Violation of any of the causes/grounds/ and the prohibited acts provided in this Act and
28 the offenses in the Revised Penal Code, the Anti-Graft and Corruption Practices and
29 other laws;

1 (c) Involvement in the manipulation, tampering or rigging of the licensure examination, its
2 questions and/or its results and the disclosure of classified and confidential information
3 pertaining to the licensure examination.

4 (d) Conviction of an offense involving moral turpitude by a court of competent jurisdiction.

5 The Commission, in the conduct of investigation shall be guided by Section 7, and
6 Section 15 of R.A. No. 8981 and the rules on administrative investigation thereof, and the
7 applicable provisions of the New Rules of Court.

8 9 **ARTICLE III**

10 **EXAMINATION, REGISTRATION, CERTIFICATION, AND LICENSURE**

11
12 **SEC. 12. - *Passing of Licensure Examination Requirement.*** – Except as otherwise
13 specifically allowed under this Act, applicants for registration for the practice of pharmacy shall
14 be required to pass a licensure examination as provided for in this Act and in accordance with
15 Sec. 7 (d) of R.A. No. 8981.

16
17 **SEC. 13. - *Qualifications of Applicants.*** – An applicant for the licensure examination
18 for pharmacy shall satisfactorily show that he/she possesses the following qualifications:

19 (a) Citizen of the Philippines or a foreign citizen whose country/state has reciprocity with the
20 Philippines in the practice of pharmacy;

21 (b) Of good moral character and reputation;

22 (c) A holder of a Bachelor's degree in pharmacy duly recognized or accredited by the
23 Commission on Higher Education (CHED) and conferred by a school/ college/university
24 duly authorized by the government or its equivalent degree obtained by either a Filipino
25 or foreign citizen from an institution of learning in a foreign country/state, provided it is
26 duly recognized and/or accredited by CHED;

27 (d) Not convicted of an offense involving moral turpitude by a court of competent
28 jurisdiction; and

1 (e) He must have completed an Internship Program which shall consist of at least nine
2 hundred sixty hours (960 hours), six hundred hours (600 hours) of which shall be spent
3 equally distributed in a community pharmacy, hospital pharmacy, or pharmaceutical
4 industry – manufacturing, regulatory, marketing, or research – and other related fields,
5 while three hundred sixty hours (360 hours) of internship shall be spent in any of the
6 accredited pharmacy establishments or entity chosen by the candidate.

7 For this purpose, the abovementioned community pharmacy, pharmaceutical company,
8 and hospital pharmacy shall keep a separate record of pharmacy students who underwent said
9 internship program directly under their control and as a result thereof, shall issue the proper
10 certificate of said hours of internship. It shall also be the duty of said establishments to submit
11 semi-annually a complete report of the names of those who have undergone training under their
12 supervision and the corresponding number of hours of internship credit of each of the pharmacy
13 students to their respective colleges or schools and to the Board.

14
15 **SEC. 14. Scope of Examination.** – The licensure examination for pharmacists shall be
16 divided into two major divisions: Pharmacy as Science and Pharmacy as Practice. Pharmacy as
17 Science shall consist of subjects in Group I (Manufacturing, Quality Control I and II, and Legal
18 Pharmacy and Ethics), Group II (Chemistry and Pharmacy of Medicinals I, and Chemistry and
19 Pharmacy of Medicinals II, Pharmacognosy and Plant Chemistry, and Pharmaceutical
20 Biochemistry), Group III (Physical Pharmacy, Biopharmaceutics and Pharmacokinetics,
21 Pharmacology I and II).

22 Pharmacy as Practice shall be made up of the following subjects: Group IV
23 (Pharmaceutical Calculations, Drug Delivery Systems, and Pharmaceutical Administration and
24 Management), Group V (Microbiology and Parasitology, Public Health, and Clinical
25 Toxicology), and Group VI (Hospital Pharmacy, Clinical Pharmacy, and Dispensing and
26 Medication Counseling).

27 The subjects shall be weighted as follows: Group I, 15%; Group II, 15%; Group III, 20%;
28 Group IV, 15%; Group V, 15%; and Group VI, 20 %.

1 The Board subject to the approval by the Commission may introduce relevant changes, as
2 the need arises, to the content of the examination and the relative weight attributed to each
3 subject in the examination may be made after consultation with the duly recognized association
4 of schools or colleges of pharmacy and the CHED.

5
6 **SEC. 15. *Holding of Examination.*** – Examination for registration to practice pharmacy
7 in the Philippines shall be given twice a year in such places and dates as the Commission may
8 designate in the Resolution thereof on the Master Schedules for all licensure examinations in
9 accordance with Sec. 7 (d) of R.A. No. 8981. The said places and dates may be subject to change
10 under valid circumstances and reasons.

11
12 **SEC. 16. *Ratings in the Licensure Examination.*** – In order to be registered and licensed
13 as a pharmacist, a candidate must obtain a general weighted average of seventy-five per cent
14 (75%).

15
16 **SEC. 17. *Report of Rating.*** –The Board shall submit to the Commission the ratings
17 obtained by each candidate within three (3) calendar days after the examination, unless extended
18 for just cause. Upon the release of the results of the examination, the Commission shall send by
19 mail the rating received by each examinee at his/her given address using the mailing envelope
20 submitted during the examination.

21
22 **SEC. 18. *Oath of Profession.*** – All successful candidates in the licensure examination
23 shall take their oath of profession before the Chairman or any member of the Board or any
24 authorized officer of the Commission to administer oaths, prior to entering the practice of
25 pharmacy.

26
27 **SEC. 19. *Issuance of Certificate of Registration and Professional Identification Card.***
28 – A certificate of registration shall be issued to those who are registered upon payment of fees

1 prescribed by the Commission. It shall bear the signatures of the Chairperson and the
2 Commissioners of the Commission and the Chairman and Members of the Board, stamped with
3 the official seal of the Commission and of the Board, certifying the person named therein is
4 entitled to the practice of the profession with all the privileges appurtenant thereto. Until revoked
5 or suspended in accordance with this Act, it shall remain in full force and effect.

6 A professional identification card bearing the registration number and date, its validity
7 and expiry duly signed by the Chairperson of the Commission shall likewise be issued to every
8 registrant who has paid the prescribed fee.

9
10 **SEC. 20. *Affixing R.Ph. after a Registered Pharmacist's Name.*** – Only pharmacists
11 who are duly registered and licensed by the Board and the Commission has the right to affix the
12 title, “Registered Pharmacist” or “R.Ph.” after his/her name.

13
14 **SEC. 21. *Grounds for Non-registration.*** – The Board shall not register any successful
15 examinee for registration who has been:

- 16 (a) Convicted of an offense involving moral turpitude by a court of competent jurisdiction,
17 (b) Found guilty of immoral or dishonorable conduct by the Board,
18 (c) Adjudged guilty for violation of the General Instructions to Examinees by the Board,
19 (d) Declared of unsound mind by the court of competent jurisdiction, and
20 (e) Found addicted to dangerous drugs.

21 In refusing such registration, the Board shall give the applicant a written statement setting
22 forth the reasons therefor and shall file a copy in its records.

23
24 **SEC. 22. *Reissuance of Revoked Certificate of Registration, Replacement of Lost or***
25 ***Damaged Certificate of Registration, Professional Identification Card or Temporary/Special***
26 ***Permit.*** – The Board may upon petition, reinstate or reissue a revoked certificate of registration
27 two (2) years from the date of its revocation. The Board may or may not require the pharmacist
28 whose certificate had been revoked to take another licensure examination. The petitioner shall
29 prove to the Board that he/she has valid reason/s to be reinstated to the practice of pharmacy. For

1 the grant of his/her petition, the Board shall issue a Board Resolution subject to the approval of
2 the Commission.

3 Duplicate copy of lost or damaged certificate of registration, professional identification
4 card or temporary/special permit may be reissued in accordance with rules thereon and upon
5 payment of the prescribed fee therefor.

6
7 **SEC. 23. *Non-payment of the PRC Registration Fees.*** - The Board shall suspend a
8 registered pharmacist from the practice of his/her profession for non-payment of the PRC
9 registration fees for more than three (3) consecutive years from its last or previous year of
10 payment. The resumption of his/her practice shall take place only upon payment of delinquency
11 fees plus surcharges and interest and in accordance with the rules of the Commission. The
12 running of the three-year period may be interrupted upon written notice about the discontinuance
13 of his/her practice and surrender of his/her certificate of registration with professional
14 identification card to the Board and/or the Commission.

15
16 **SEC. 24. *Vested Rights; Automatic Registration.*** - All pharmacists registered before the
17 effectivity of this Act shall automatically be registered hereunder, subject to the policy as to
18 future requirements. Certificates of registration and professional identification cards or
19 temporary/special permits held by such persons in good standing at such effectivity shall have
20 the same force and effect as though they were issued on or after the said effectivity.

21 22 **ARTICLE IV**

23 **REGULATION OF THE PRACTICE OF PHARMACY**

24
25 **SEC. 25. *Scope of the Practice of Pharmacy.*** - A person deemed to be practicing
26 pharmacy within the meaning of this Article is one who shall, with or without a fee, salary,
27 percentage or other rewards, paid or given directly to himself or indirectly through another -

- 1 (a) Prepare, compound or manufacture, analyze, assay, preserve, store, distribute, sell and/or
2 dispense any medicine, drug, chemicals, cosmetics, pharmaceuticals, devices or
3 contrivances used in pursuance thereof; or,
4 (b) render services not limited to drug information service and medication management
5 whenever the expertise and the technical knowledge of the pharmacist is required; or,
6 (c) render services not limited to regulatory services, pharmaceutical marketing, and the
7 conduct or undertaking of scientific research in all aspects involving drugs and
8 healthcare in collaboration with other qualified professional; or,
9 (d) engage in teaching scientific, technical or professional pharmacy courses in a school or
10 college of pharmacy; or
11 (e) conduct or undertake scientific research in all aspects involving drugs and healthcare; or
12 (f) dispense drugs during medical missions and in other situations where supervision of
13 drugs is required; or,
14 (g) provide other services where pharmaceutical knowledge is required.

15 All government and non-government agencies, establishments, institutions, and
16 regulatory body with functions that directly involve the practice of pharmacy shall preferably be
17 headed and managed by a qualified, duly registered and licensed pharmacist.

18 All pharmacists are expected to abide by current standards such as the Good Pharmacy
19 Practice, Good Laboratory Practice, Good Distribution Practice, Good Manufacturing Practice,
20 and Good Clinical Practice, which are deemed vital in the performance of one's roles and
21 functions in different practice areas.

22 The Board, subject to the approval by the Commission, may add to, delete, or modify the
23 above acts, services, or activities as the need arises.

24
25 **SEC. 26. Prerequisites for the Practice of Pharmacy.** – A person can practice pharmacy
26 in the Philippines provided he/she:

- 27 (a) has satisfactorily passed the licensure examination for pharmacists given by the Board
28 and the Commission;
29 (b) is duly registered with and licensed by the Board and the Commission; and,

1 (c) is an active member of the accredited integrated national professional organization.

2
3 **SEC. 27. *Foreign Reciprocity.*** – No foreigner shall be allowed to take the licensure
4 examination for pharmacists, register, receive his/her certificate of registration and professional
5 identification card, and practice pharmacy in the Philippines unless the requirements for the
6 licensure examination and registration and practice of pharmacy imposed under the laws and the
7 regulations in his/her foreign country or state are substantially the same as those required and
8 contemplated by the Philippine laws and regulations, and unless the said foreign laws and
9 regulations allow Filipino citizens to practice pharmacy within the territory of the said foreign
10 country/state on the same basis and grant the same privileges as those enjoyed by the citizens,
11 subjects or nationals thereof.

12
13 **SEC. 28. *Practice through Temporary/Special Permit.*** – A temporary/ special permit
14 may be issued by the Board subject to the approval of the Commission and payment of
15 applicable fees to the following:

16 (a) licensed pharmacists from foreign countries whose services whether for free or a fee

17 (1) if they are internationally renowned pharmacists or experts in any field or
18 specialty of pharmacy,

19 (2) if their services are deemed necessary for lack of specialists or experts in a
20 particular field,

21 (b) licensed pharmacists from foreign countries or states whose services shall be for free and
22 limited to indigent patients as beneficiaries; or

23 (c) licensed pharmacists from foreign countries or states employed as visiting faculty in a
24 field or specialty of pharmacy.

25 The permit shall, among other things, contain these limitations and conditions for a
26 period of no more than one year, subject to renewal, the field or specialty of pharmacy, and the
27 specific place of practice including clinics, hospitals, and schools of pharmacy. The Board
28 subject to the approval by the Commission shall promulgate rules and regulations on the
29 implementation of this particular Section.

1 **SEC. 29. Indication of Numbers: Certificate of Registration, Professional Tax Receipt**
2 **and Accredited Integrated National Organization (AIPO) Membership.** – The pharmacist shall
3 be required to indicate on any document he/she signs, uses or issues in connection with the
4 practice of pharmacy the following information:

5 (a) his/her registration number and date of issuance,

6 (b) the expiration date of his/her professional identification card,

7 (c) the Professional Tax Receipt (PTR) Number and date of issuance, and

8 (d) the certificate of AIPO membership (annual/lifetime) number and the official receipt of
9 payment, number and date.

10 **SEC. 30. Registry of Pharmacists.** – The Board shall prepare and maintain a registry of
11 the names, residences and/or office addresses of all registered pharmacists which shall be
12 updated annually in cooperation with the Accredited Integrated Professional Organization
13 (AIPO), indicating therein the status of the certificate of registration, professional identification
14 card and Accredited Integrated Professional Organization (AIPO) membership, whether valid or
15 inactive due to death, or other reasons, delinquent, suspended or with revoked certificate of
16 registration. The said registry of pharmacists shall be conspicuously posted within the premises
17 of the Commission and the information therein made available to the public upon inquiry or
18 request.

19
20 **SEC. 31. Display of Certificate of Registration.** – It shall be the duty of every pharmacist
21 engaged in the practice of pharmacy either on his/her own account or under the employ of
22 another to display his/her original certificate of registration in a prominent and conspicuous place
23 in a retail drug outlet or drug establishment which he operates or in which he/she is employed in
24 his/her professional capacity as pharmacist. No pharmacist shall, with his/her knowledge, allow
25 his/her certificate of registration to be displayed in such establishment when he/she is not
26 actually employed or operating therein in his/her professional capacity.

27 A photocopy of the registration certificate duly certified by the Board shall be displayed
28 in Category B establishments as described in Section 33 of this Act.

1
2 **SEC. 32. Sale of Drugs, Medicines, Pharmaceuticals, Biopharmaceuticals, Medicated**
3 **Cosmetics, and Medical Devices.** – No drug, medicines, pharmaceuticals, biopharmaceuticals,
4 medicated cosmetics, and medical devices of whatever nature and kind shall be compounded,
5 dispensed, sold or resold, or otherwise be made available to the consuming public except through
6 a FDA-licensed retail drug outlet or other business establishments which are duly established in
7 accordance with the provisions of applicable laws.

8 Prescription drugs and pharmacist-only over-the-counter drugs, medicines or
9 pharmaceutical products shall be dispensed by a duly registered pharmacist except only in
10 emergency case where the services of a registered and licensed pharmacist are not available.
11 *Provided,* that prescription drugs and pharmacist-only over-the-counter drugs, medicines or
12 pharmaceutical products are sourced only in pharmacies under the direct control, supervision and
13 responsibility of a registered pharmacist.

14 Compounding and dispensing shall be done only by duly registered and licensed
15 pharmacists in accordance with current good manufacturing practice, good laboratory practice,
16 and good pharmacy practice with the safety and protection of individual patients as ultimate
17 objective. A registered and licensed pharmacist may refuse to compound, dispense or sell drugs
18 and pharmaceutical products, if not in accordance with this Act.

19 Licensed manufacturers, importers, distributors and wholesalers of drugs, medicines,
20 medicated cosmetics, pharmaceutical and biopharmaceuticals are authorized to sell their
21 products only to duly licensed drug outlets, wholesalers and other drug establishments.
22

23 **SEC. 33. Pharmacist Requirement and Compensation.** –

24 *Category A.* Establishments where the direct and immediate control, supervision and
25 responsibility of a registered and licensed pharmacist is required at all times when open for
26 business include:

- 27 i. Every drug establishment/outlet selling prescription drugs and medicines, ethical
28 products, pharmacists-only over-the-counter drugs and medicines and medicated

1 cosmetics whether owned by the government or a private person or firm, whether
2 sold at wholesale or retail,

- 3 ii. Each operation of pharmaceutical laboratories, pharmaceutical manufacturing
4 laboratories or other establishments with processes involving the preparation,
5 manufacture, quality control, repacking, importation, exportation, distribution,
6 sale or transfer of pharmaceutical products and medicated cosmetics in quantities
7 greatly in excess of single therapeutic doses

8 *Category B.* Establishments where supervision and oversight of a registered and licensed
9 pharmacist is required pursuant to the provision of pertinent laws include:

- 10 i. Retail outlets selling over-the-counter drugs only
11 ii. Establishments involved in the manufacture, importation, exportation, distribution
12 and sale of medical devices.
13 iii. Institutional pharmacies providing medicines to employees and their relatives
14 iv. Government agencies including local government units, city and municipal health
15 units, and, private establishments involved in the procurement, distribution,
16 dispensing and storage of drugs and medicines
17 v. Institutions providing telepharmacy services
18 vi. Other non-traditional outlets of drugs and medicines provided no prescription or
19 ethical products are sold

20 The Board, subject to the approval by the Commission, may add, delete, or modify the
21 above list of establishments as the need arises in order to be able to keep pace with developments
22 in the industry.

23 Pharmacists in government service shall receive a starting salary equivalent to Salary
24 Grade 15 as provided in R.A. 6758 (Compensation and Position Classification Act of 1989) and
25 its amendments. Pharmacists in the private sector shall receive an entry-level salary in peso
26 equivalent of at least 35% above the prevailing minimum wage.

27 A pharmacist working in a Category A establishment may be allowed to simultaneously
28 work or render pharmacy services in not more than two Category B establishments, provided
29 that the Category B establishments are within a ten (10) kilometer radius from the Category B

1 establishment. A photocopy of the Pharmacist's registration certificate duly certified by the
2 Board shall be displayed in such Category B establishments.

3
4 **SEC. 34. Responsibility for Quality of Drugs, Cosmetics and Medical Devices.** – It shall
5 be the duty of the registered pharmacist of drug outlet/establishment to ensure that all drug
6 products, cosmetics and medical devices conform to standards of safety, quality and efficacy and
7 strictly adhere to the guidelines as provided for in this Act and other pertinent rules and
8 regulations and issuances. Owners, managers, and/or pharmacists in charge of the operation of
9 drug outlets and drug establishments shall be held responsible.

10 It shall be unlawful for any person to manufacture, prepare, sell or dispense any
11 prescription drug, pharmaceutical, medical devices, or cosmetics under any fraudulent name,
12 direction or pretense or to adulterate any drug, pharmaceutical, medical devices, or cosmetics
13 offered for sale. Any drug, pharmaceutical product, medical device/s or cosmetics shall be held
14 to be adulterated or deteriorated within the meaning of this section if it differs from the standard
15 or quality or purity given in the United States Pharmacopeia/National Formulary and Philippine
16 Pharmacopeia, in its latest edition, or any standard reference for drugs and medicines given
17 official recognition, and those which fall within the meaning as provided for in the Food Drug,
18 Cosmetic and Devices Act, R.A. No. 3720, as amended by pertinent laws and the Food and Drug
19 Administration Act or R.A. 9711.

20 In cases of drug products sold in their original package, the seal of which has not been
21 broken or tampered with, the liability that may arise because of their quality and purity, rests
22 upon the manufacturer or importer, the distributor, representative, or dealer who is responsible
23 for their distribution or sale.

24
25 **SEC. 35. Filling and Partial Filling of Prescription.** - All prescriptions shall be
26 filled or compounded only by a registered and licensed pharmacist following the standards of
27 purity, safety and quality. Completely filled prescriptions should be surrendered to the
28 pharmacist for recording.

1 Partial filling of prescription is dispensing units less than the total quantity indicated in
2 the prescription. The prescription should contain information as to how many units were served
3 and shall be returned to the buyer after being recorded in the appropriate book or equivalent
4 system. The drugstore, which completes the filling of the prescription, shall keep the prescription
5 on file for a prescribed period of time.

6 Ethical preparations may be dispensed only with a valid prescription by a doctor, dentist
7 or veterinarian.

8
9 **SEC. 36. *Physician's sample.*** – Drugs, biologic products, devices or proprietary
10 medicines, given or intended to be given free to the physician and other qualified person by any
11 manufacturer or distributor or its medical representative as part of its program or promotion,
12 should not be sold.

13 The statement “Sample, not for sale” shall appear conspicuously on the container,
14 package, or carton of the drug or device to be given. It shall be unlawful to remove, erase, deface
15 already marked original labels of samples.

16 No physician's sample for drugs classified as antibiotics or anti-infectives, including anti-
17 TB may be given or distributed.

18
19 **SEC. 37. *Prohibition against use of cipher or unusual terms in prescriptions and***
20 ***prescription switching*** – Pharmacists should not compound or dispense prescriptions, recipes or
21 formulas which are written in ciphers, codes or secret keys or prescriptions of drugs using
22 unusual names which differ from those in standard pharmacopeias or formularies.

23 The pharmacist dispensing or compounding prescriptions should not substitute the drug
24 or drugs called for in the prescription with any other drug or substance or ingredient without
25 prior consultation with, and a written consent of the person prescribing, except in accordance
26 with RA 6675, known as the Generics Act of 1988, and other pertinent laws and regulations.

27
28 **SEC. 38. *Label of Dispensed Medicines.*** - Upon every box, bottle or package containing
29 medicine compounded or dispensed by a registered and licensed pharmacist based on

1 prescription, there shall be pasted, affixed or imprinted a seal or label bearing, among others,
2 name of patient, generic name of drug; brand name, if any, strength, expiry date, directions for
3 use, and name and address of drugstore and other requirements prescribed by the Cheaper
4 Medicines Act (RA 9502) and its implementing rules and regulations.

5 Every prescription which in its preparation contains any quantity of a drug, which is
6 habit-forming, or a derivative of such drug, shall have an auxiliary label or a notation, "Warning
7 – May be habit forming". Such prescriptions should comply with the requirements of the RA
8 9165, the Comprehensive Dangerous Drugs Act of 2002, or other applicable laws.

9 Prescription for external use shall be filled with an auxiliary label bearing, "For External
10 Use."

11

12 **SEC. 39. Record Books for Prescription.** – All prescriptions dispensed in the drugstore
13 shall be recorded in the book or an equivalent recording system approved by FDA for this
14 purpose indicating therein, among others, the prescription number, name of prescriber, generic
15 name and brand, dosage strength, quantity of drug, name of the patient and address, and initials
16 of pharmacist. It shall be open to inspection by the proper authorities at any time of the day when
17 the pharmacy is open to the public and must be preserved for a period of not less than two (2)
18 years after the last entry.

19 All prescriptions shall be attached to the prescription book or compiled and numbered
20 consecutively and shall be preserved for the same period of time as required.

21 All required information on dangerous drugs dispensed by a pharmacy shall be recorded
22 in the Dangerous Drugs book or an equivalent recording system as required by R.A. 9165, or
23 other applicable laws.

1 members thereof and shall receive all the benefits and privileges accorded to its members upon
2 payment of the required fees and dues. Membership to the foregoing shall not be a bar to
3 membership in any other association of pharmacists.

4 All pharmacy assistants shall be accredited by the Board and shall *ipso facto* become
5 members of the AIPO and included in the registry of pharmacy assistants.

6

7 **SEC. 43. *Membership in the Accredited Integrated Professional Organization of***
8 ***Pharmacists.*** – All registered pharmacists and pharmacy assistants must be members of the
9 AIPO and must maintain membership throughout the duration of the practice of the profession.
10 Professional identification card shall not be renewed if the requirements for membership with
11 AIPO are not met including credit units for attendance at duly accredited continuing professional
12 development (CPD) education activities.

13

14 **SEC. 44. *Specialty Boards in Various Areas of Pharmacy Practice.*** – Specialty
15 Boards shall be created within the affiliate organizations and societies for recognition of the
16 AIPO. The Board, subject to the approval of the Commission, shall accredit specialties in
17 various areas of practice, set standards of practice within different specialties, and establish the
18 qualifications and requirements for certification of practitioners under each specialty.

19

20

ARTICLE VI

21

VIOLATIONS, ADMINISTRATIVE SANCTIONS, AND PROCEDURES

22

23 **SEC. 45. *Revocation or Suspension of the Certificate of Registration and Cancellation***
24 ***of Temporary or Special Permit.*** – The Board shall have the power, upon notice and hearing to
25 revoke or suspend the certificate of registration of a registered pharmacist or to cancel a
temporary or special permit granted to a foreign pharmacist on the basis of the following:

26

27

28

- (a) Violation of this Act on unauthorized practice of pharmacy, violation of any provision of this Act, the Implementing Rules and Regulations (IRR) thereof, the Code of Ethics for Pharmacists, Code of Good Governance, Code of Technical

- 1 Standards for the practice of pharmacy, policy, and measure of the Board and/or the
2 Commission and other applicable laws;
- 3 (b) Dishonorable conduct and/or conviction by a competent court of any offense in the
4 Revised Penal Code, the Anti-Graft and Corruption Practices and other laws, or
5 offense involving moral turpitude;
- 6 (c) Malpractice or gross incompetence; negligence, or imprudence resulting to death or
7 injury of the patient;
- 8 (d) Fraud or deceit in the acquisition of the certificate of registration, professional
9 identification card or temporary/special permit or renewal of license;
- 10 (e) Display of certificate of registration of a pharmacist who is not actually employed in
11 such an establishment as required by law;
- 12 (f) Addiction to alcoholic beverages or to any habit-forming drug rendering him
13 incompetent to practice his/her profession;
- 14 (g) Aiding or abetting the illegal practice of a non-registered and licensed person by
15 allowing him/her the use of his/her certificate of registration and/or professional
16 identification card or his/her special/temporary permit;
- 17 (h) Acting as a dummy of an alien or a person who is not qualified to establish and
18 operate a retail drugstore;
- 19 (i) Insanity or any mental disorder that would render the person incompetent to practice
20 his/her profession;
- 21 (j) False, extravagant or unethical advertisements and product endorsements where the
22 pharmacist's name, professional organization he/she represents, and similar
23 information are used;
- 24 (k) Manufacture, sale, offering for sale of counterfeit drugs and committing other acts in
25 violation of Sec. 4 of the Special Law on Counterfeit Drugs, R.A. No. 8203;
- 26 (l) Illegal manufacturing, sale, possession, dispensing of dangerous drugs and other
27 pertinent acts in violation of Dangerous Drugs Act, R.A. No. 9165 and other
28 applicable laws;
- 29 (m) Committing acts in violation of Sec. 6 of P.D. No. 881 on Hazardous Substances;

- 1 (n) Practicing pharmacy while under suspension;
- 2 (o) Practicing with an expired professional identification card;
- 3 (p) Operating and/or dispensing drugs through online pharmacy.

4

5 **SEC. 46. *Grounds for Non-renewal of license.*** - The following are the grounds for the
6 non-renewal of professional identification card:

- 7 (a) Refusal to join or to remain a member of good standing of the AIPO;
- 8 (b) Non-payment of annual registration fees for three (3) continuous years;
- 9 (c) Non-compliance with the continuing professional development requirement, for the
10 renewal of his/her professional identification card; and

11 The Board shall periodically evaluate the aforementioned grounds and revise as the need
12 arises subject to the approval of the Commission.

13 Any person, entity or organization may file charges according to the provision of this section
14 against any registrant, or the Board may investigate violation of any of the abovementioned
15 causes. Affidavit of complaint under oath shall be filed together with the affidavits of witnesses
16 and other documentary evidence with the Board through the Legal and Investigation Office. The
17 move to conduct an investigation shall be embodied in a formal charge to be signed by at least a
18 majority of the members of the Board. The rules on administrative investigation issued by the
19 Commission shall govern the hearing or investigation subject to applicable provisions of this
20 Act, R.A. No. 8981 and its rules and regulations thereof, and Rules of Court.

21

22 **SEC. 47. *Administrative Investigation/Sanctions.*** - Administrative investigations shall
23 be conducted by the Board assisted by the Legal or Hearing Officer of the Commission. The
24 existing rules of evidence shall also be observed and applied during administrative
25 investigations.

26 If the Board, by a majority vote of the members, shall find that the charges are sustained
27 by evidence adduced, it may, at its discretion reprimand the respondent or revoke or suspend his
28 certificate of registration.

1 **SEC. 48. Procedure and Rules.** – The Board upon receipt of a formal complaint under
2 oath against any pharmacist shall furnish the latter a copy of the complaint, which shall be
3 answered in writing within ten (10) days from receipt thereof. If the Board, after careful study of
4 the records, finds that there is a valid ground to the charge, it shall conduct a formal investigation
5 and set the dates of the hearing thereof. For this purpose, a subpoena and/or subpoena *duces*
6 *tecum* may be issued by the chairman of the Board or by the Chief, Legal and Investigation
7 Division. The investigation proceedings shall at all times be recorded. The investigation shall
8 have been terminated and resolved within ninety (90) days from the time the first date of hearing
9 shall be set and heard.

10

11 **SEC. 49. Rights of Respondent.** - The respondent pharmacist is entitled to be heard or be
12 represented by counsel; to have speedy public hearing, to confront, and to cross-examine the
13 witness or witnesses against him; to summon and present witness or witnesses in his behalf; or to
14 avail himself/herself of any other process for the protection of his/her constitutional rights.

15

16 **SEC. 50. Motion for Reconsideration.** – A motion for reconsideration within the,
17 prescribed period may be made based on any of the following grounds:

- 18 (a) Grave abuse of discretion by the Board;
- 19 (b) Findings not supported by substantial evidence; and,
- 20 (c) Irregularity in the conduct of investigation.

21

22 **SEC. 51. Appeal/Finality of Decision.** - The decision of the Board shall automatically
23 become final and executory fifteen (15) days from the appropriate service of the decision to the
24 respondent, unless the latter within the same period, has appealed the decision to the
25 Commission; provided that said decision of the Commission may be appealed to the Court of
26 Appeals.

- 1 (i) Preparation and compounding of pharmaceutical products in quantities greatly in excess
2 of single therapeutic doses without a registered pharmacist
- 3 (j) Non-compliance with the labeling requirement for dispensed medicines by a drug outlet
- 4 (k) Allowing pharmacy assistants to dispense without the supervision of a pharmacist
- 5 (l) Manufacturing and selling of pharmaceutical products under fraudulent name and
6 address
- 7 (m) Adulteration and misbranding of drugs
- 8 (n) Manufacturing and selling of unsafe, substandard and counterfeit drugs
- 9 (o) Operating an online pharmacy service or selling of drugs online (Section 32)

10 *Requirement of Pharmacist (Sections 33, 35)*

- 11 (p) Category A establishments which open for business without a licensed pharmacist
- 12 (q) Category B establishments which are not under the supervision of a licensed pharmacist
- 13 (r) Compounding by a non-registered pharmacist or a pharmacist with an expired license
- 14 (s) Filling of prescription by a non-pharmacist or a non-registered pharmacist or a
15 pharmacist with expired license.
- 16

17 **SEC. 53. Other Penalties.** - Any person who shall violate any of the following provisions of
18 this Act shall upon conviction, be sentenced to a fine of not less than One Hundred Thousand
19 (Php100,000.00) Pesos but not exceeding Two Hundred Thousand (Php200,000.00) Pesos or to
20 an imprisonment of not less than Thirty (30) days but not more than One (1) year, or both
21 penalty and fine at the discretion of the court, thus:

- 22 (a) Affixing of the title, R.Ph. by a person who is not a pharmacist duly registered by the
23 Board (Section 20)
- 24 (b) Practice of pharmacy in the Philippines by a foreigner without special permit (Section 28)
- 25 (c) Non-indication by a pharmacist of his/her registration number and Professional Tax
26 Receipt number in official documents requiring such information (Section 29)
- 27 (d) Failure to display original certificate of registration of a pharmacist in a drug
28 establishment requiring such (Section 31)

- 1 (e) Refusal to display certificate of registration of a pharmacist in a prominent and
2 conspicuous place by an establishment/outlet (Section 31)
- 3 (f) Refusal by an establishment to comply with compensation requirement as provided in
4 Section 33 of this Act
- 5 (g) Non-compliance by a pharmacist with the requirement on the filling of prescription
6 (Section 35)
- 7 (h) Non-compliance by a registered pharmacist on the requirement for partially filled
8 prescription (Section 35)
- 9 (i) Selling of physician's samples (Section 36)
- 10 (j) Distribution of physician's samples of drugs classified as antibiotics, anti-infectives or
11 anti-TB (section 36)
- 12 (k) The removal, erasure and alteration of mark or label of physician's sample (Section 36)
- 13 (l) The use of cipher, codes or secret keys or unusual names or terms in prescriptions (Sec
14 37)
- 15 (m) Filling of Prescriptions where cipher, codes, secret keys or unusual names and terms are
16 used (Sec 37)
- 17 (n) Non-compliance with the Provisions on Record Books for Prescription by a drug outlet
18 (Section 39)
- 19 (o) Employment of persons in a pharmacy or pharmaceutical operation without the provision
20 of the required training and certification (Section 41)
- 21 (p) Rendering dispensing-related services by non-pharmacists in a drug establishment
22 without undergoing the required training (Section 41)

23 Any person other than the citizens of the Philippines having been found guilty of any
24 violation as provided for in this and the preceding section shall, after having paid the fine or
25 having served his sentence or both when so adjudged, be also subject to immediate deportation.

26 For any violation of the provisions of this Act penalized under this and the preceding
27 section, which also constitutes or considered as punishable offense or described as a violation of

1 other laws, the applicable penalty shall be that of the law providing for a higher fine and/or
2 imprisonment.

3 For any violation of the rules and regulations implementing the provisions of this Act,
4 appropriate penalty shall be imposed.

5

6

ARTICLE VIII

7

FINAL PROVISIONS

8

9 **SEC. 54. *Enforcement.*** – The Commission shall be the enforcement agency of this Act.
10 As such, the Commission shall implement the appropriate provisions of this Act, enforce its
11 implementing rules and regulations as adopted by the Board, assist the Board in the investigation
12 of complaints against violators of this Act, its rules and regulations, Code of Ethics for
13 pharmacists, professional standards, and other policies of the Board and the Commission.

14 The Commission and/or the Board shall call upon or request any department,
15 instrumentality, office, bureau, institution or agency of the government, including local
16 government units to render such assistance as it may require, or to coordinate or cooperate in
17 order to carry out, enforce or implement the provisions of this Act.

18

19 **SEC. 55. *Appropriations.*** – The Chairperson of the PRC shall immediately include in its
20 programs on the implementation of this Act, the funding of which shall be charged against their
21 current years' appropriations and thereafter, in the annual General Appropriations Act.

22 **SEC. 56. *Transitory Provisions.***– The incumbent Chairman and members of the Board
23 shall, in an interim capacity, continue to function as such until the Chairman and members of the
24 new Board created under this Act shall have been appointed, constituted and/or organized
25 pursuant thereto.

26

27 **SEC. 57. *Implementing Rules and Regulations.*** – Within one hundred and twenty (120)
28 days after the approval of this Act, the Board subject to the approval by the Commission, in

1 consultation with the AIPO, shall issue and formulate the implementing rules and regulations, as
2 well as the Code of Ethics and professional standards for pharmacists, to effectively implement
3 this Act.

4

5 **SEC. 58. *Separability Clause.*** – If any clause, provisions, paragraph or part hereof shall
6 be declared unconstitutional or invalid, such judgment shall not affect, invalidate, impair any
7 other part thereof, but such judgment shall be merely confined to the clause, provision, paragraph
8 or part directly involved in the controversy in which such judgment has been rendered.

9

10 **SEC. 59. *Repealing clause.*** – R.A. No. 5921, known as the Pharmacy Law, as amended
11 by E.O. No. 174, and PD No. 1363, and all other laws inconsistent herewith are hereby repealed,
12 Presidential decrees, executive orders, and other administrative issuances and parts thereof which
13 are inconsistent with the provisions of this Act are hereby modified, amended, superseded and/or
14 repealed accordingly.

15

16 **SEC. 60. *Effectivity.*** – This Act shall take effect after fifteen (15) days following the full
17 and complete publication thereof in the *Official Gazette* or in two (2) major daily newspaper of
18 general circulation in the Philippines.

Approved,